Eli Lilly and Company

Eli Lilly and Company, a Pharmaceutical Preparation Manufacturing company headquartered in GB, reported its 2025 emissions as approximately 8.6 billion kg CO2e. This total includes Scope 1 emissions of 206 million kg CO2e, market-based Scope 2 emissions of 208 million kg CO2e, and Scope 3 emissions of 8.22 billion kg CO2e.

Looking back, in 2024, the company's total emissions were approximately 6.6 billion kg CO2e, with Scope 1 emissions at 192 million kg CO2e, market-based Scope 2 emissions at 258 million kg CO2e, and Scope 3 emissions at 6.174 billion kg CO2e. For 2023, total emissions were around 5.8 billion kg CO2e, comprising Scope 1 emissions of 182 million kg CO2e, market-based Scope 2 emissions of 345 million kg CO2e, and Scope 3 emissions of 5.1395 billion kg CO2e.

Eli Lilly and Company has set climate targets, aiming for carbon neutrality in its own operations (Scope 1 and 2 emissions) by 2030. The company also reported a 26% absolute emissions reduction in its own operations (Scope 1 and 2) from 2020 to 2023. Additionally, a target was set for a 20% reduction of facility energy GHG emissions (Scope 1 onsite fuel combustion and location-based Scope 2) per square foot by the end of 2020, against a 2012 baseline. In 2019, they achieved a 16% reduction, making 80% progress towards this target.